Moxidectin is a second generation macrocyclic lactone of the milbemycin family.

For the treatment and control of adult and larval stages of important internal parasites including encysted inhibited EL3 and developing intramucosal L4 larval stages of small redworms, arterial stages of large redworms and bots in horses and ponies with a single dose.

EQUEST Oral Gel, at the recommended dosage level of 400 mcg moxidectin per kg bodyweight, provides effective control of moxidectin sensitive strains of the following parasites of horses and ponies:

Large strongyles:

Strongylus vulgaris (adults and arterial stages)

Strongylus edentatus (adults and visceral stages)

Triodontophorus brevicauda (adults)

Triodontophorus serratus (adults)

Triodontophorus tenuicollis (adults)

Small strongyles (adults and intraluminal larval stages):

EQUEST Oral Gel is effective against (developing) intramucosal L4 stages of small strongyles. At eight weeks after treatment early (hypobiotic) EL3 stages of small strongyles are eliminated.

EQUEST Oral Gel is effective against benzimidazole resistant strains of cyathostomes.

Ascarids:

Parascaris equorum (adult and larval stages)

Other species:

Oxyuris equi (adult and larval stages)

Habronema muscae (adults)

Gasterophilus intestinalis (L2, L3)

Gasterophilus nasalis (L2, L3)

Strongyloides westeri (adults)

EQUEST Oral Gel has a persistent effect in preventing infection by small strongyles for 2 weeks after dosing and suppresses the presence of small strongyle eggs in the dung for 90 days.